Are GlaxoSmithKline plc And Legal & General Group Plc Great Dividend Picks For 2016 And Beyond?

Is now the perfect time to buy high-yielding GlaxoSmithKline plc (LON:GSK) and Legal & General Group Plc (LON:LGEN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are some cracking dividends on offer at the moment among the elite companies of the FTSE 100.

The index itself currently yields 3.9%, but a number of individual stocks are flaunting considerably higher yields.

Today, I’m looking at whether GlaxoSmithKline (LSE: GSK) at 5.8% and Legal & General (LSE: LGEN) at 5.2% are great dividend picks for 2016 and beyond.

Should you invest £1,000 in Barclays right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Barclays made the list?

See the 6 stocks

GlaxoSmithKline

GlaxoSmithKline has faced a number of headwinds in recent years, as have its big pharma peers. Constrained public health budgets, expiring patents and competition from generics have hit top- and bottom-line growth. For Glaxo, a bribery scandal in China hasn’t helped, either.

The table below show some key earnings and dividend data for the company.

  2012 2013 2014 2015 forecast 2016 forecast
Earnings per share growth (%) -2 -4 -12 -20 +11
Dividend per share growth (%) +6 +5 +3 0 0
Dividend cover 1.5x 1.4x 1.2x 0.9x 1.1x

As you can see, earnings began to decline at an accelerating rate from 2012, yet management continued to increase the dividend each year, with the result that dividend cover began to drop.

Obviously, a trajectory of falling earnings and rising dividends can’t continue indefinitely, and earlier this year — with earnings forecast to plunge 20% — Glaxo’s management took the decision to hold the 2015 dividend at the same 80p level as 2014. And also intends to hold it at 80p for 2016 and 2017.

As the table shows, earnings won’t quite cover the 2015 dividend. However, the good news is that analyst are expecting Glaxo to return to earnings growth in 2016, with an 11% rise, which reflects guidance from the company itself. Earnings would then be back to covering the dividend, albeit by a slim 1.1x.

Additionally, though, Glaxo has taken steps to help it get through the dip in dividend cover. As well as the ordinary dividend, management had originally intended to pay a special dividend of a further 80p for 2015, out of cash realised from a deal with Novartis. However, the Board has decided to reduce the special to 20p; thus retaining most of the cash from Novartis, effectively making the ordinary dividend more secure through the next couple of years of lean cover.

Obviously, investors can’t expect to see an increase in Glaxo’s dividend until after 2017 — and rises for a few years thereafter are likely to lag earnings growth, until the company has rebuilt dividend cover, probably to around the 1.5x level. However, the current high starting yield of 5.8% (excluding the 20p one-off special dividend) appears good compensation, and now could be a good time to buy a slice of this world-class business.

Legal & General

In contrast to Glaxo, Legal & General has been on a roll in recent years. The insurer and asset manager has been increasing earnings at a good clip, and shareholders have seen tasty annual rises in their dividends.

The table below show some key earnings and dividend data for the company.

  2012 2013 2014 2015 forecast 2016 forecast
Earnings per share growth (%) +11 +10 +10 +14 +7
Dividend per share growth (%) +20 +22 +21 +19 +7
Dividend cover 1.8x 1.6x 1.5x 1.4x 1.4x

As you can see, while Glaxo has been suffering falling earnings, L&G has been knocking out regular double-digit annual growth — and increasing the dividend at twice the rate of earnings.

Management has been keen that shareholders benefit from the recovery since the financial crisis, but we should note that the generous dividend payouts have brought cover down from 1.8x to an expected 1.4x this year. The boom period for dividend growth is over, and L&G is expected to increase payouts in line with earnings growth going forward, maintaining dividend cover at around 1.4x.

L&G is a strong business, and mid-to-high single digit earnings and dividend growth looks sustainable for the foreseeable future. The forecast 2016 dividend gives a yield of 5.2%, which appears highly attractive when combined with the company’s decent growth prospects for the years ahead.

Should you buy Barclays now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At $184, I reckon this S&P 500 juggernaut is still on sale

Our writer sees Amazon (NASDAQ:AMZN) as an attractive S&P 500 stock to consider while it is priced 23% lower than…

Read more »

Investing Articles

Cheap FTSE 250 shares to consider buying right now?

These FTSE 250 growth stocks had weak starts to 2025, and face short-term uncertainty. But their long-term valuations could be…

Read more »

Investing Articles

As stocks dive, is this a rare chance for ISA investors to build generational wealth?

Globally, stocks have pulled back significantly following the announcement of tariffs by the US president. Is this an opportunity for…

Read more »

Investing Articles

2 ultra-cheap shares to consider right now!

These cheap UK shares offer considerable growth and income potential over the long term, reckons our writer Royston Wild.

Read more »

Investing Articles

Legal & General Group shares go ex-dividend on 24 April – time to grab that 9% yield?

Harvey Jones holds Legal & General Group shares and is already looking forward to the next bumper dividend from this…

Read more »

Young female analyst working at her desk in the office
Investing Articles

3 FTSE 100 dividend stocks to consider buying while they’re on sale

Paul Summers reckons canny investors should think about snapping up quality, dividend-paying stocks while they're going cheap

Read more »

Investing Articles

2 cheap passive income shares to consider buying right now

The passive income we can earn from the UK stock market looks set to climb this year, and could even…

Read more »

Investing Articles

Down 15% in a month, this FTSE 100 dividend share offers investors a stunning 10.8% yield

Harvey Jones plucks out a FTSE 100 dividend share that offers frankly a quite staggering yield and is now a…

Read more »